CanSense Group

CanSense’s test, which combines laser spectroscopy with artificial intelligence, is faster, less expensive and less invasive than a colonoscopy procedure and more acceptable for patients than a faecal blood detection kit. It could help detect bowel cancer at an early stage when it is much easier to treat and the chance of survival is much higher. Studies have shown that it can detect pre-malignant polyps, before they develop into cancer. It can also rule out cancer with a high degree of accuracy and could therefore help GPs decide which patients to refer for further investigations. Currently less than one in ten patients who have a colonoscopy are found to have cancer and unnecessary procedures are estimated to cost the NHS around £300m a year.